(Q33636635)

28 July 2017

1 reference

title

Systematic review of intravitreal bevacizumab injection for treatment of primary diabetic macular oedema (English)

1 reference

28 July 2017

1 reference

1 reference

Taygan Yilmaz

1

1 reference

28 July 2017

Miguel Cordero-Coma

series ordinal

2

1 reference

28 July 2017

Michéal J Gallagher

series ordinal

3

1 reference

28 July 2017

Laura A Teasley

series ordinal

4

1 reference

28 July 2017

publication date

20 July 2010

1 reference

28 July 2017

1 reference

28 July 2017

volume

89

1 reference

28 July 2017

issue

8

1 reference

28 July 2017

page(s)

709-717

1 reference

Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.01918.X

A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.01918.X

A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.01918.X

Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.01918.X

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.01918.X

A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.01918.X

Efficacy of intravitreal bevacizumab (Avastin) for short-term treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.01918.X

Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.01918.X

Systemic adverse events after bevacizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.01918.X

Intravitreous anti-VEGF for diabetic retinopathy: hopes and fears for a new therapeutic strategy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.01918.X

Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.01918.X

Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.01918.X

Intravitreal triamcinolone acetonide injection for treatment of refractory diabetic macular edema: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-3768.2010.01918.X

10.1111/J.1755-3768.2010.01918.X

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference